Previously, we reported our experience treating 14 patients with metastatic melanoma using a fully human antibody to cytotoxic T-lymphocyte antigen-4 (anti–CTLA-4) in conjunction with peptide ...
For decades, cancer immunotherapy has focused primarily on CD8+ cytotoxic T lymphocytes as the main executors of tumor cell ...
In a recent study published in Nature Immunology, researchers investigated the direct influence of sodium (Na+) ions on the cytotoxic cluster of differentiation 8 (CD8)-expressing T cells and hence on ...
Cancer immunotherapy has revolutionized treatment for many patients, but significant challenges remain in predicting who will respond to these life-saving treatments. A new comprehensive review ...
Therapeutically targeting the CALR/CD47 pathway in MPN to reactivate natural immunosurveillance mechanisms within the body to enhance treatment outcomes. This is an ASCO Meeting Abstract from the ASCO ...
CD8 + cytotoxic T lymphocytes (CTLs) serve as central effectors in cancer immunotherapy by directly eliminating tumor cells. However, current clinical therapies face significant limitations. These ...
CD4+ T cells, long regarded as supporting actors in cancer immunity, are emerging as central regulators of tumor control and ...
Immunostimulant therapy using agonistic cytokines or activating antibodies has been associated with off-target side effects, failure to preferentially activate cytotoxic lymphocytes (CTLs) over ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results